Actinogen Strengthens Funding to Support Completion of XanaMIA Alzheimers Trial
Actinogen Medical Limited (ASX: ACW) has secured firm commitments to raise approximately AU$ 12.0 million through a capital raising via a share placement to sophisticated and professional investors, providing funding beyond the expected topline final results from the XanaMIA Alzheimer’s disease trial in November 2026. The placement will be completed at an issue price of AU$ 0.042 per share through the issue of approximately 285.7 million new shares, with Director participation subject to shareholder approval. Proceeds are expected to fund completion of the pivotal XanaMIA trial, implementation of the open-label extension phase, and general corporate purposes. The Company also plans to launch a share purchase plan to raise up to AU$5.0 million (with oversubscriptions permitted), bringing the total raise to approximately AU$17.0 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Actinogen Strengthens Funding to Support Completion of XanaMIA Alzheimers Trial
Actinogen Medical Limited (ASX: ACW) has secured firm commitments to raise approximately AU$ 12.0 million through a capital raising via a share placement to sophisticated and professional investors, providing funding beyond the expected topline final results from the XanaMIA Alzheimer’s disease trial in November 2026. The placement will be completed at an issue price of AU$ 0.042 per share through the issue of approximately 285.7 million new shares, with Director participation subject to shareholder approval. Proceeds are expected to fund completion of the pivotal XanaMIA trial, implementation of the open-label extension phase, and general corporate purposes. The Company also plans to launch a share purchase plan to raise up to AU$5.0 million (with oversubscriptions permitted), bringing the total raise to approximately AU$17.0 million.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au